Equillium/$EQ
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Equillium
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
- Ticker
- $EQ
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 15
- Headquarters
- La Jolla, United States
- Website
- www.equilliumbio.com
Equillium Metrics
BasicAdvanced
$111M
-
-$0.20
1.81
-
Price and volume
Market cap
$111M
Beta
1.81
52-week high
$3.54
52-week low
$0.76
Average daily volume
480K
Financial strength
Current ratio
23.396
Quick ratio
23.069
Long term debt to equity
0.003
Total debt to equity
0.01
Profitability
EBITDA (TTM)
-19.2
Management effectiveness
Return on assets (TTM)
-33.95%
Return on equity (TTM)
-58.98%
Valuation
Price to book
1.61
Price to tangible book (TTM)
1.61
Price to free cash flow (TTM)
-6.469
Free cash flow yield (TTM)
-15.46%
Free cash flow per share (TTM)
-0.22
Growth
Earnings per share change (TTM)
-65.62%
3-year earnings per share growth (CAGR)
-28.04%
What the Analysts think about Equillium
Analyst ratings (Buy, Hold, Sell) for Equillium stock.
Analyst projections of the future price of Equillium stock.
Equillium Financial Performance
Revenues and expenses
Equillium Earnings Performance
Company profitability
Upcoming events
No upcoming events
Equillium News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.